EQRx and Geisinger Sign MOU to Reduce Costs of Innovative Cancer...

EQRx and Geisinger Sign MOU to Reduce Costs of Innovative Cancer Medicines

Healthcare Tech Outlook | Monday, January 24, 2022

Geisinger and EQRx have signed an MOU for the provision of access to innovative cancer medicines at radically lower prices.

FREMONT, CA: “We are committed to partnering with different types of health systems worldwide to increase access to medicines, and we are thrilled to collaborate with Geisinger, a leading integrated delivery network,” states Melanie Nallicheri, EQRx’s Chief Executive Officer. EQRx, a new breed of pharmaceutical company dedicated to developing and delivering transformative new medicines to patients at radically reduced prices, signs a non-binding memorandum of understanding (MOU) with Geisinger, a leading integrated delivery network in the United States. The MOU lays the groundwork for Geisinger and EQRx to enter into a commercial agreement that would provide Geisinger members and patients access to EQRx's pipeline of innovative medicines, subject to FDA approval. The MOU envisions an expansion of the two organizations' existing long-term strategic collaboration with the shared goal of bringing innovative therapies to the people served by Geisinger in a financially sustainable manner.

“The MOU provides a roadmap for access to future EQRx products, beginning with our two lead oncology programs, and paves the way to delivering these lower-cost, innovative medicines to the more than one million people within Geisinger health systems upon FDA approval,” adds Melanie.

The parties anticipate that the commercial agreement will initially focus on EQRx's two lead oncology programs, aumolertinib, and sugemalimab, but may expand to include additional EQRx pipeline programs. Both aumolertinib, an EGFR inhibitor, and sugemalimab, an anti-PD-L1 antibody, have shown promising Phase 3 data in patients with advanced non-small-cell lung cancer.

“Our partnership with EQRx is well aligned with Geisinger's commitment to our community to make better health easier by directly addressing the rising costs of healthcare and medications in particular,” states Mike Evans, chief pharmacy officer of Geisinger. “Ballooning medication costs are placing an unsustainable burden on both patients and the U.S. healthcare system. This partnership marks Geisinger's commitment to disrupt the status quo and help make lower-cost medications for our patients a reality.”

Weekly Brief